Category: 875444-08-9

Electric Literature of 875444-08-9, Chemistry is the experimental science by definition. We want to make observations to prove hypothesis. For this purpose, we perform experiments in the lab. 875444-08-9, Name is (4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one,introducing its new discovery.

The present invention discloses an optical pure aromatic hydrocarbon process for the preparation of beta-amino alcohol, which is characterized by comprising the following steps: D or L-amino acid with the starting materials or chloroformic acid benzyl ester CBz-Cl bitter wine acid reaction to obtain compound I-1 BOC; I-1 the compound with paraformaldehyde in a solvent reflux dehydration obtained compound in A I-2; compound I-2 yu Geshi reagent reaction, dilute hydrochloric acid treatment to obtain compound I-3; compound I-3 used can be aluminum isopropoxide catalytic reduction. The purpose of this invention is to overcome the shortcomings of the prior art, to provide a cheap and easily obtained materials to help to reduce the, simple preparation process, the resulting intermediate structure is stable process for the preparation of pharmaceutical intermediates. (by machine translation)

Balanced chemical reaction does not necessarily reveal either the individual elementary reactions by which a reaction occurs or its rate law.Electric Literature of 875444-08-9. In my other articles, you can also check out more blogs about 875444-08-9

Reference：
Oxazolidine – Wikipedia,
Oxazolidine | C3H2779NO – PubChem

Application of 875444-08-9, A catalyst don’t appear in the overall stoichiometry of the reaction it catalyzes, but it must appear in at least one of the elementary reactions in the mechanism for the catalyzed reaction. 875444-08-9, Name is (4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one, molecular formula is C12H9F6NO2. In a Patent，once mentioned of 875444-08-9

The present invention relates to the field of organic chemistry, more specifically to the synthesis of intermediate compounds which can be used in the synthesis of pharmaceutically active agents such as anacetrapib or derivatives thereof.

A reaction mechanism is the microscopic path by which reactants are transformed into products. Each step is an elementary reaction. In my other articles, you can also check out more blogs about 875444-08-9

Reference：
Oxazolidine – Wikipedia,
Oxazolidine | C3H2777NO – PubChem

SDS of cas: 875444-08-9, Chemistry is the experimental science by definition. We want to make observations to prove hypothesis. For this purpose, we perform experiments in the lab. 875444-08-9, Name is (4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one,introducing its new discovery.

CCompounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compound of Formula I, A3 is a substitiuted phenyl group or indanyl group.Formula (I)

I am very proud of our efforts over the past few months and hope to 875444-08-9 help many people in the next few years. SDS of cas: 875444-08-9

Reference：
Oxazolidine – Wikipedia,
Oxazolidine | C3H2771NO – PubChem

COA of Formula: C12H9F6NO2, As a society publisher, everything we do is to support the scientific community – so you can trust us to always act in your best interests, and get your work the international recognition that it deserves. 875444-08-9, Name is (4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one, molecular formula is C12H9F6NO2. In a Patent，once mentioned of 875444-08-9

The present invention relates to a long interfering dsRNA (liRNA) capable of promoting an immune reaction as well as inhibiting the expression of specific RNAi-mediated target genes, and to uses thereof. More particularly, the present invention relates to a long interfering dsRNA capable of inducing the expression of interferon-beta by stimulating, depending on a structure, a protein kinase R (PKR) path as well as inhibiting the expression of specific target genes through an RNA-interfering reaction through a specific sequence.

You can get involved in discussing the latest developments in this exciting area about 875444-08-9. COA of Formula: C12H9F6NO2

Reference：
Oxazolidine – Wikipedia,
Oxazolidine | C3H2757NO – PubChem

Chemistry graduates have much scope to use their knowledge in a range of research sectors, including roles within chemical engineering, chemical and related industries, healthcare and more. Related Products of 875444-08-9,

Compounds having the structure of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), B is a cyclic group other than phenyl, and B has a cyclic substituent at a position that is ortho to the position at which B is connected to the remainder of the structure of Formula (I). The 5-membered ring of Formula (I) has a second cyclic substituent in addition to B.

You can also check out more blogs about 875444-08-9Related Products of 875444-08-9

Reference：
Oxazolidine – Wikipedia,
Oxazolidine | C3H2761NO – PubChem

Computed Properties of C12H9F6NO2, As a society publisher, everything we do is to support the scientific community – so you can trust us to always act in your best interests, and get your work the international recognition that it deserves. 875444-08-9, Name is (4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one, molecular formula is C12H9F6NO2. In a Article，once mentioned of 875444-08-9

SAR studies of the substitution effect on the central phenyl ring of the biphenyl scaffold were carried out using anacetrapib (9a) as the benchmark. The results revealed that the new analogs with substitutions to replace trifluoromethyl (9a) had a significant impact on CETP inhibition in vitro. In fact, analogs with some small groups were as potent or more potent than the CF3 derivative for CETP inhibition. Five of these new analogs raised HDL-C significantly (>20 mg/dL). None of them however was better than anacetrapib in vivo. The synthesis and biological evaluation of these CETP inhibitors are described.

The potential utility of systematic synthetic strategy will be applicable to efficient generations of chemical libraries of compounds to find ‘hit’ molecules.Read on for other articles about 875444-08-9Computed Properties of C12H9F6NO2

Reference：
Oxazolidine – Wikipedia,
Oxazolidine | C3H2783NO – PubChem

Recommanded Product: (4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one, In chemical reaction engineering, simulations are useful for investigating and optimizing a particular reaction process or system. 875444-08-9, Name is (4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one, molecular formula is C12H9F6NO2. In a Patent，once mentioned of 875444-08-9

Disclosed are a novel oxazolidinone derivative exhibiting inhibitory activity against CETP, a preparation method thereof, and a pharmaceutical composition comprising the same. Exhibiting excellent inhibitory activity against CETP, the oxazolidinone derivative can be effectively applied to the prevention or treatment of various CETP enzyme activity- or HDL cholesterol level-related diseases such as dyslipidemia, atherosclerosis, and coronary heart disease.

We’ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 875444-08-9, and how the biochemistry of the body works.Recommanded Product: (4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one

Reference：
Oxazolidine – Wikipedia,
Oxazolidine | C3H2773NO – PubChem

Related Products of 875444-08-9, Modeling chemical reactions helps engineers virtually understand the chemistry, optimal size and design of the system, and how it interacts with other physics that may come into play.In a article, mentioned the application of 875444-08-9, Name is (4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one, molecular formula is C12H9F6NO2

We describe our optimization efforts to improve the physicochemical properties, solubility, and off-target profile of 1, an inhibitor of TarO, an early stage enzyme in the biosynthetic pathway for wall teichoic acid (WTA) synthesis. Compound 1 displayed a TarO IC50 of 125 nM in an enzyme assay and possessed very high lipophilicity (clogP = 7.1) with no measurable solubility in PBS buffer. Structure-activity relationship (SAR) studies resulted in a series of compounds with improved lipophilic ligand efficiency (LLE) consistent with the reduction of clogP. From these efforts, analog 9 was selected for our initial in vivo study, which in combination with subefficacious dose of imipenem (IPM) robustly lowered the bacterial burden in a neutropenic Staphylococci murine infection model. Concurrent with our in vivo optimization effort using 9, we further improved LLE as exemplified by a much more druglike analog 26.

Future efforts will undeniably focus on the diversification of the new catalytic transformations. These may comprise an expansion of the substrate scope from aromatic and heteroaromatic compounds to other hydrocarbons. Keep reading other articles of 875444-08-9. Related Products of 875444-08-9

Reference：
Oxazolidine – Wikipedia,
Oxazolidine | C3H2784NO – PubChem

SDS of cas: 875444-08-9, Modeling chemical reactions helps engineers virtually understand the chemistry, optimal size and design of the system, and how it interacts with other physics that may come into play.In a article, mentioned the application of 875444-08-9, Name is (4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one, molecular formula is C12H9F6NO2

An efficient process is disclosed for producing the compound of formula I, which is the CETP inhibitor anacetrapib, which raises HDL-cholesterol and reduces LDL-cholesterol in human patients and may be effective for treating or reducing the risk of developing atherosclerosis:

The reactant in an enzyme-catalyzed reaction is called a substrate. Enzyme inhibitors cause a decrease in the reaction rate of an enzyme-catalyzed reaction.I hope my blog about 875444-08-9 is helpful to your research. SDS of cas: 875444-08-9.

Reference：
Oxazolidine – Wikipedia,
Oxazolidine | C3H2762NO – PubChem

875444-08-9, Name is (4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one, belongs to oxazolidine compound, is a common compound. Related Products of 875444-08-9In an article, once mentioned the new application about 875444-08-9.

The compound of Formula I, including pharmaceutically acceptable salts, is a CETP inhibitor, and is useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compound of Formula 1, R is H or C1-6alkyl optionally substituted with 1-3 halogens: (Formula I).

A reaction mechanism is the microscopic path by which reactants are transformed into products. Each step is an elementary reaction. In my other articles, you can also check out more blogs about 875444-08-9

Reference：
Oxazolidine – Wikipedia,
Oxazolidine | C3H2778NO – PubChem